Skip to main content
. 2020 Feb 26;8(2):e00566. doi: 10.1002/prp2.566

Figure 4.

Figure 4

Effect of CB1 antagonist on the SCRA‐mediated cAMP signaling peaks in HEK‐CB1 cells. A, Traces from a representative experiment showing that SCRA (JWH‐018, 5F‐MDMB‐PICA, and AB‐FUBINACA) induced observed stimulatory effects were inhibited by SR141716A (CB1 antagonist, 3 μmol L−1) pretreatment. B, Scatter dot plot representing SCRAs‐mediated stimulation of forskolin (3 µmol L−1)‐induced cAMP response in presence and absence of SR141716A 3 µmol L−1 on HEK 293 cells expressing CB1. Within each set SCRAs (10 µmol L−1) were compared to SCRAs + SR141716 (unpaired Student's t test, P < .05 marked with *). Data were normalized to forskolin (FSK, 100%) and vehicle (0%), and plotted as mean ± SEM for at least five independent experiments performed in duplicate. cAMP, cyclic adenosine monophosphate; CB1, cannabinoid receptor type 1; HEK, human embryonic kidney; SCRA, synthetic cannabinoid receptor agonist